Endometriosis, a reproductive condition affecting roughly 1 in 10 women worldwide, can now be detected through a non-invasive saliva test called Endotest, following approval from the National Institute for Health and Care Excellence (NICE) in the UK. According to Yale Medicine, women face an average wait of 11 years between their first symptoms and a formal diagnosis of the disease, which occurs when uterine tissue grows outside the uterus to cause chronic pain, cramping, and complications like a frozen pelvis or infertility.
How Endotest Detects Endometriosis From Saliva Samples
The Endotest diagnostic tool checks a patient’s saliva sample for specific microRNAs that indicate whether endometriosis is present, according to NICE. While NICE noted that the product is not meant to serve as a standalone diagnostic tool, it has received approval for use in clinicians’ offices across England and Wales for a three-year period. Dr. Gail Busby, a consultant gynaecologist at Manchester University NHS Foundation Trust, stated in a press release that the test provides answers much earlier without requiring invasive surgery.
Before the introduction of saliva screening, diagnosing the condition required extensive medical workups. Dr. Sheeva Talebian, a board-certified reproductive endocrinologist, previously told The Post that patients often undergo colonoscopies, endoscopies, and abdominal MRIs yet still receive no clear findings. Talebian noted that endometriosis remains one of the most common missed diagnoses because doctors lack effective blood tests or imaging modalities to catch the disease in its early stages.
Did you know? Affecting approximately 10% of women globally, endometriosis symptoms extend beyond painful periods to include fatigue, joint pain, shortness of breath, irritable bowels, urinary frequency, and infertility.
Clinical Challenges and the Impact of Delayed Diagnosis
The progression of endometriosis does not always correspond to symptom severity, according to medical specialists. Talebian explained that in severe cases, chronic inflammation and scar tissue cause a condition known as a frozen pelvis, where the ovaries, bladder, and bowel fuse together and distort internal anatomy. Furthermore, the disease impacts fertility by diminishing ovarian reserve and physically blocking fallopian tubes.
Talebian stated she was haunted by how long “we’ve conditioned women to believe that debilitating pain is normal,” adding that even gynecologists may miss varying symptoms and refer patients to other specialists. By providing an alternative to prolonged diagnostic journeys, tools like Endotest aim to streamline clinical workflows. Busby noted that an earlier diagnosis frees up medical appointments and surgical slots for other patients waiting for care.
Frequently Asked Questions
What is Endotest?
Endotest is a saliva-based test that checks for microRNAs indicating the presence of endometriosis. It is approved for clinician office use in England and Wales for three years, following NICE approval.
How long does it typically take to diagnose endometriosis?
According to Yale Medicine, women wait an average of 11 years between experiencing their first symptoms and receiving a formal diagnosis.
What are the common symptoms of endometriosis?
Symptoms include cramping, chronic pain, fatigue, joint pain, shortness of breath, irritable bowels, urinary frequency, and infertility, though some women experience no history of painful periods or pelvic pain.
Explore more health insights, share your thoughts in the comments below, or subscribe to our newsletter to receive the latest updates on reproductive medicine developments.
- Brain Tumor Patients Demand More Treatment Options
- Urgent Call for Chronic Pain Model of Care
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)